Genetic polymorphisms of cytochrome P450 2B6 (CYP2B6) are associated with lower rate of EFV metabolism and lead to high exposure, as well as a higher risk of neuropsychiatric adverse event especially homozygous variant CYP2B6 \*6/\*6. This trial was designed to compare the proportion of patients who had undetectable HIV RNA at 24 weeks after ART initiation between patient who did CYP 2B6 guided EFV dose and who did not.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
190
There will be adjusted dose of efavirenz in CYP2B6 guide group
If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
All patients will be monitored drug level which should be in therapeutic level.
Faculty of medicine Ramathibodi Hospital
Bangkok, Bangkok, Thailand
RECRUITINGHIV RNA
Time frame: 24 weeks
Neuropsychiatric adverse events
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.